Gelesis Holdings (Gelesis Holdings) Debt-to-EBITDA : -3.06 (As of Jun. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Gelesis Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gelesis Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $33.91 Mil. Gelesis Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $27.96 Mil. Gelesis Holdings's annualized EBITDA for the quarter that ended in Jun. 2023 was $-20.20 Mil. Gelesis Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -3.06.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Gelesis Holdings's Debt-to-EBITDA or its related term are showing as below:

GLSHQ' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.54 Med: -1.01 Max: -0.75
Current: -1.54

During the past 2 years, the highest Debt-to-EBITDA Ratio of Gelesis Holdings was -0.75. The lowest was -1.54. And the median was -1.01.

GLSHQ's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.325 vs GLSHQ: -1.54

Gelesis Holdings Debt-to-EBITDA Historical Data

The historical data trend for Gelesis Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gelesis Holdings Debt-to-EBITDA Chart

Gelesis Holdings Annual Data

Trend

Dec21

Dec22

Debt-to-EBITDA

-0.75

-1.28

Gelesis Holdings Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Debt-to-EBITDA	Get a 7-Day Free Trial					-0.77	-1.15	-0.75	-9.15	-3.06

Competitive Comparison of Gelesis Holdings's Debt-to-EBITDA

For the Biotechnology subindustry, Gelesis Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gelesis Holdings's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gelesis Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gelesis Holdings's Debt-to-EBITDA falls into.

Gelesis Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Gelesis Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(35.954	+	26.309)	/	-48.821
	=	-1.28

Gelesis Holdings's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(33.912	+	27.963)	/	-20.2
	=	-3.06

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.

Gelesis Holdings (OTCPK:GLSHQ) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Gelesis Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gelesis Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Gelesis Holdings (Gelesis Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gelesis Holdings Inc (OTCPK:GLSHQ) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

501 Boylston Street, Suite 6102, Boston, MA, USA, 02116

Website

https://www.gelesis.com

Gelesis Holdings Inc is a biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Its portfolio includes Plenity, an FDA-cleared product to aid in weight management, as well as potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

Executives

Raju S Kucherlapati	director	77 LOUIS PASTEUR AVENUE, BOSTON MA 02115
Bomsmaster Llc	10 percent owner	195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Hpso Spv Ltd	10 percent owner	SARNIA HOUSE, LE TRUCHOT, ST PETER PORT Y7 GY1 4NA
Alessandro Sannino	officer: Lead Project Scientist	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Dominic Perks	director	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON NY 02116
David A. Pass	officer: Chief Op. & Comm. Officer	GELESIS, INC., 501 BOYLSTON STREET, SUITE 1602, BOSTON MA 02116
Elaine Chiquette	officer: Chief Scientific Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Jane Wildman	director	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Harry L. Leider	officer: Chief Medical Officer	C/O GELESIS, INC., 501 BOYLSTON STREET, SUITE 6102, BOSTON MA 02116
Clayton Christopher	director	2407 S. CONGRESS AVE, SUITE E103, AUSTIN TX 78704
Health Plc Puretech	10 percent owner	6 TIDE STREET, SUITE 400, BOSTON MA 02210
Ssd2, Llc	10 percent owner	142 TEMPLE STREET, SUITE 206, NEW HAVEN CT 06511
Yishai Zohar	director, officer: President & CEO	C/O GELESIS, INC., 501 BOYLSTON ST., SUITE 6102, BOSTON MA 02116
Elon Boms	10 percent owner	C/O THIMBLE POINT ACQUISITION CORP., 195 CHURCH STREET, 15TH FLOOR, NEW HAVEN CT 06510